NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 18.7% and is now trading at $204.27.
View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.23. The medical instruments supplier earned $226.30 million during the quarter, compared to analysts' expectations of $212.41 million. Insulet had a net margin of 2.20% and a return on equity of 24.43%. The business's revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.02 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

20 Wall Street analysts have issued 1 year price targets for Insulet's stock. Their forecasts range from $165.00 to $260.00. On average, they expect Insulet's stock price to reach $223.00 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Insulet.

Headlines about PODD stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Alibaba Group (BABA), Netflix (NFLX), salesforce.com (CRM), Tesla (TSLA), Roku (ROKU), Square (SQ), Trade Desk (TTD) and Walt Disney (DIS).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mint Tower Capital Management B.V. (12.74%), William Blair Investment Management LLC (1.43%), Frontier Capital Management Co. LLC (1.29%), Victory Capital Management Inc. (0.66%), Sumitomo Mitsui Trust Holdings Inc. (0.49%) and KAMES CAPITAL plc (0.48%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Russell Investments Group Ltd., Chartwell Investment Partners LLC, First Trust Advisors LP, GW&K Investment Management LLC, KAMES CAPITAL plc, Sumitomo Mitsui Trust Holdings Inc., and Amalgamated Bank. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., SeaTown Holdings Pte. Ltd., Jag Capital Management LLC, Jennison Associates LLC, Frontier Capital Management Co. LLC, Granite Investment Partners LLC, Columbus Circle Investors, and State of Alaska Department of Revenue.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $204.27.

Insulet has a market capitalization of $12.89 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]